BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.325
-0.005 (-0.07%)
As of 12:53PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.330
Open7.300
Bid7.320 x 1300
Ask7.340 x 1000
Day's Range7.250 - 7.490
52 Week Range4.120 - 8.130
Volume209,288
Avg. Volume749,014
Market Cap801.223M
Beta2.02
PE Ratio (TTM)N/A
EPS (TTM)-0.831
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.25
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst an additional $3.5 million to support clinical trials of galidesivir in patients with yellow fever. Yellow fever represents a significant unmet medical need and a new potential use of galidesivir. With this additional $3.5 million contract amendment, the NIAID development contract for galidesivir now totals $43.0 million.

  • What Sarepta Therapeutics’ Valuation Trend Indicates
    Market Realist7 days ago

    What Sarepta Therapeutics’ Valuation Trend Indicates

    Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.

  • Here's Why BioCryst Pharmaceuticals Rose 21.3% in August
    Motley Fool10 days ago

    Here's Why BioCryst Pharmaceuticals Rose 21.3% in August

    Believe it or not, share prices rose after the company announced a share offering.

  • RTP pharma scores $35M contract to supply CDC
    American City Business Journals14 days ago

    RTP pharma scores $35M contract to supply CDC

    Research Triangle Park-based pharma just scored what could be a $35 million contract to manufacture influenza treatments.

  • MarketWatch14 days ago

    BioCryst stock surges 6% premarket after winning $35 million CDC contract for flu therapy

    BioCryst Pharmaceuticals Inc. shares (bcrx) surged more than 6% premarket on the news that it has won a $35 million, five-year contract from the Centers for Disease Control and Prevention for up to 50,000 doses of its antiviral flu therapy Rapivab. The CDC will place the medication in the Strategic National Stockpile, a supply of potentially life-saving medicines for use in a public-health emergency. Rapivab is used to treat acute flu in patients two years and older who have shown symptoms for more than two days.

  • GlobeNewswire14 days ago

    CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile

    BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a $34.7 million contract for the procurement of up to 50,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period. The CDC’s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency. “We appreciate the CDC acknowledging the value of RAPIVAB to patients and our national security,” said Jon Stonehouse, chief executive officer of BioCryst.

  • Benzinga15 days ago

    The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Biotech Stocks Hitting 52-week highs on Sept. 4) Aptinyx Inc (NASDAQ: APTX ) Becton Dickinson and Co ...

  • Inside The List: Highest-Paid Public Company CEOs
    American City Business Journals16 days ago

    Inside The List: Highest-Paid Public Company CEOs

    In its annual analysis of highest-paid CEOs of Triangle-based publicly traded companies, Triangle Business Journal parses the data in a myriad of ways that peers beyond the numbers.

  • GlobeNewswire16 days ago

    CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks

    In a release issued under the same headline earlier today by BioCryst Pharmaceuticals, Inc. (BCRX), please note that in the first line of the table, the values for the change from baseline in VAS score through 4 hours under BCX7353 Treated Attacks and Placebo Treated Attacks are numbers, not percentages as previously published. Please also note a footnote has been added to the end of the table within the release, which notes baseline composite VAS scores for both BCX7353 treated attacks and placebo treated attacks. RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p

  • GlobeNewswire16 days ago

    BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks

    BioCryst Pharmaceuticals, Inc. (BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p

  • GlobeNewswire22 days ago

    BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Aug. 29, 2018-- BioCryst Pharmaceuticals, Inc. today announced that the company will present at the Baird Global Healthcare Conference in New York on Thursday, September 6, ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of BCRX earnings conference call or presentation 7-Aug-18 3:00pm GMT

    Q2 2018 BioCryst Pharmaceuticals Inc Earnings Call

  • GlobeNewswirelast month

    New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cincinnati ...

  • BioCryst banks gross proceeds of $57.5M from offering
    American City Business Journalslast month

    BioCryst banks gross proceeds of $57.5M from offering

    BioCryst (Nasdaq: BCRX) has raised $57.5 million in a public offering of its common stock, according to the company, with the underwriters’ option to purchase additional shares exercised in full. BioCryst, based in Research Triangle Park, said Monday that the company has been granted Fast Track Designation by the U.S. Food and Drug Administration for its product to prevent angioedema attacks in patients with hereditary angioedema, or HAE. Proceeds of the company’s public offering will be used for further development of that product candidate – known as BCX7353 – as well as for other corporate purposes, according to BioCryst.

  • BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
    Zackslast month

    BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

    BioCryst (BCRX) delivered earnings and revenue surprises of 17.39% and 228.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    BioCryst: 2Q Earnings Snapshot

    On a per-share basis, the Durham, North Carolina-based company said it had a loss of 19 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    BioCryst Reports Second Quarter 2018 Financial Results

    RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018-- BioCryst Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2018.. “Building on the clear direction from our shareholders ...

  • GlobeNewswirelast month

    BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares of its common stock, including 1,363,636 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from this offering to BioCryst, including from the shares sold pursuant to the underwriters’ option to purchase additional shares, were approximately $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst.

  • BioCryst gets FDA nod on key drug
    American City Business Journalslast month

    BioCryst gets FDA nod on key drug

    A key drug for BioCryst Pharmaceuticals (Nasdaq: BCRX) is now on the fast track, according to the U.S. Food and Drug Administration amid its shift to a standalone strategy. BioCryst, based in Research Triangle Park, said Monday that it has been granted Fast Track Designation by the FDA for a product designed to prevent angioedema attacks in patients with hereditary angioedema.

  • GlobeNewswirelast month

    U.S. FDA Grants Fast Track Designation for BioCryst’s BCX7353

    BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Company has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for BCX7353 for the prevention of angioedema attacks in patients with hereditary angioedema (HAE). Fast Track Designation provides opportunities for frequent interactions with the FDA during development of a product candidate and provides the opportunity for priority review if supported by clinical data at the time of the new drug application (NDA) submission.

  • After Idera deal called off, BioCryst looks to raise $50M
    American City Business Journals2 months ago

    After Idera deal called off, BioCryst looks to raise $50M

    Less than a month after shareholders of Research Triangle Park-based BioCryst Pharmaceuticals blocked the company’s proposed merger with Exton, Pennsylvania-based Idera Pharmaceuticals, BioCryst is looking to raise $50 million in a public offering of the company’s common stock.  BioCryst (Nasdaq: BCRX) has priced a public offering of about 9 million shares of its common stock at $5.50 per share. It has also granted underwriters a 30-day option to purchase up to about 1.4 million additional shares.  The company recently initiated a Phase 3 clinical trial of its lead drug candidate BCX7353 for the treatment of hereditary angioedema (HAE).

  • Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
    Motley Fool2 months ago

    Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

    Investors are cheering the orphan drug specialist's decision to raise a nice chunk of capital via a public offering.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 1) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CAS Medical Systems ...

  • GlobeNewswire2 months ago

    BioCryst Pharmaceuticals Prices Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock, offered at a price to the public of $5.50 per share.  The gross proceeds from this offering to BioCryst are expected to be $50 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioCryst.  BioCryst has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of its common stock.  The offering is expected to close on or about August 6, 2018, subject to customary closing conditions.

  • GlobeNewswire2 months ago

    BioCryst Pharmaceuticals Commences Public Offering of Common Stock

    BioCryst Pharmaceuticals, Inc. (BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is offering to sell $50 million of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of its common stock. J.P. Morgan and Jefferies are acting as joint book-running managers for the proposed offering.